Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
Source ↗
👁 0
💬 0
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
Comments (0)